GHRP-6
Growth Hormone Releasing Peptide-6
Popular for:Growth hormone release, appetite stimulation, gut motility
0
Registered Trials
43
Trial Publications
632
PubMed References
Animal
Evidence Level
Overview
GHRP-6 (Growth Hormone Releasing Peptide-6) is the original synthetic growth hormone releasing peptide, a hexapeptide first described in the 1980s. The short version: people usually care about it for growth hormone release, appetite stimulation, gut motility, but the strength of the evidence depends heavily on indication and study type.
GHRP-6 (Growth Hormone Releasing Peptide-6) is the original synthetic growth hormone releasing peptide, a hexapeptide first described in the 1980s. It strongly stimulates GH release through the ghrelin receptor and is known for producing significant appetite stimulation within 20-30 minutes of administration.
GHRP-6 has been extensively studied in clinical research and is one of the most well-characterized GHRPs in the literature. Its strong appetite-stimulating effects make it popular in research involving caloric intake and weight gain.
Research Snapshot
What the evidence says
AnimalGHRP-6 currently shows 0 registered trials from ClinicalTrials.gov, 43 PubMed trial publications (20 RCT-tagged), and 632 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 0 registered trials are tracked from ClinicalTrials.gov intervention records.
- 43 PubMed clinical-trial publications are indexed.
- 20 PubMed randomized controlled trial publications are indexed.
- 632 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
GHRP-6 binds to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus, triggering GH release through both direct pituitary stimulation and suppression of somatostatin.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
0
Registered Trials
43
Trial Publications
20
RCT Publications
632
PubMed References
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
0
Registered trials
43
Trial publications
20
RCT publications
632
PubMed references
26
Reviews
0
Meta-analyses
Registered trials source
Jun 1, 2026
GHRP-6
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View sourceNot FDA-approved. One of the most studied GHRPs in clinical literature. Research compound.
Key PubMed References
632 PubMed references · showing top 25 by relevance
View all on PubMedGrowth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis.
Wang L, Berlanga-Acosta J, Yu H, et al. · International immunopharmacology · 2026
PMID: 41534456Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.
Zhao X, Pan K, Li R, et al. · Journal of nanobiotechnology · 2025
PMID: 41327290Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.
Berlanga-Acosta J, Cibrian D, Valiente-Mustelier J, et al. · Frontiers in pharmacology · 2024
PMID: 38873418Ghrelin antagonist D-Lys3-GHRP-6 counteract ghrelin effects in bovine cumulus-oocytes complexes matured in vitro.
Carranza-Martín AC, Nikoloff N, Anchordoquy JP, et al. · Reproduction in domestic animals = Zuchthygiene · 2021
PMID: 34173284D-Lys-3-GHRP-6 impairs memory consolidation and downregulates the hippocampal serotonin HT1A, HT7 receptors and glutamate GluA1 subunit of AMPA receptors.
Beheshti S, Sami M, Mirzabeh A, et al. · Physiology & behavior · 2020
PMID: 32454141Anecdotes & Sentiment
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
No curated public-discussion themes are live for GHRP-6 yet.
Side Effects & Safety
- Intense hunger within 20-30 minutes - Elevated cortisol - Elevated prolactin - Water retention and bloating - Potential blood sugar fluctuations
Known Interactions
No curated interaction entry is live for GHRP-6 yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.